

January 18, 2024

To,
National Stock Exchange of India Ltd,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai-400051, India

Kind Attn.: Mr. Binoy Yohannan, Associate Vice President, Surveillance

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – clarification on reported news item

This is with reference to your e-mail dated January 17, 2024 and in relation to a news article which appeared in <https://www.financialexpress.com> on January 17, 2024, with the heading “Dr Reddy’s Laboratories eyes mega brand in UK - The Financial Express.”

In this connection, we would like to inform that *vide* our letter dated January 16, 2024, we have already clarified the reported news article. A copy of the said clarification is annexed herewith for for taking the same on record.

We reiterate that the Company does not comment on market speculations and there is currently no such event or information which requires a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’).

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

Thanking you.

Yours faithfully,
For **Dr. Reddy’s Laboratories Limited**

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR

Encl: as above.

January 16, 2024

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – information on reported news item

This is in reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) regarding a news item published in “Sky News” and available at the link: <https://news.sky.com/story/indian-pharma-group-dr-reddys-eyes-swoop-on-nicotinell-13049500> on January 16, 2024, with the heading “Indian pharma group Dr Reddy's eyes swoop on Nicotinell”.

The said news item is about “Dr Reddy's Laboratories, an Indian pharmaceutical group, is in talks to buy Nicotinell, the anti-smoking aid, from its FTSE-100 parent company”. In this regard, please note that the Company does not comment on market speculations and there is currently no such event or information which requires a disclosure under Regulation 30 of the SEBI Listing Regulations.

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

This is for your information.

Thanking you.

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

KUMAR
RANDHIR SINGH

Digitally signed by
KUMAR RANDHIR SINGH
Date: 2024.01.16
22:06:14 +05'30'

K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR